Authorized purpose: Concurrent CADe reading aid that identifies, categorizes, and highlights suspicious regions of interest on adult chest radiographs
Clinical role
Concurrent reading aid for physician interpretation, with overlay toggled in the PACS viewer; not a replacement for physician interpretation
Images and patients
X-ray/Radiography · Chest/thorax, with ROI categories covering cardiac, mediastinum/hila, lungs, pleura, bones, soft tissues, hardware, and other
Key limitation
Keep in mind: Indicated for adults only and intended as an assistive concurrent read; suspicious categories are broad ROIs rather than a single disease diagnosis, and physician interpretation remains necessary
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Concurrent CADe reading aid that identifies, categorizes, and highlights suspicious regions of interest on adult chest radiographs
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/thorax, with ROI categories covering cardiac, mediastinum/hila, lungs, pleura, bones, soft tissues, hardware, and other Input: Adult digital chest radiograph studies received from a DICOM node
Who uses it?Intended users: Physicians
What does the software produce?Output: DICOM Presentation State overlay for each image with ROI category text and bounding boxes when suspicious ROIs are detected, or No ROI(s) Detected with no boxes; overlay can be toggled in the PACS viewer
What is its most important limitation?Key limitation: Indicated for adults only and intended as an assistive concurrent read; suspicious categories are broad ROIs rather than a single disease diagnosis, and physician interpretation remains necessary
Clinical takeaway. Clinical role: Concurrent CADe reading aid that identifies, categorizes, and highlights suspicious regions of interest on adult chest radiographs
Evidence takeaway. Evidence from the reviewed source record: Standalone testing used 20,000 chest radiographs from 12 US hospitals, outpatient centers, and specialty centers: overall sensitivity 0.908 (95% CI 0.905-0.911), specificity 0.887 (0.885-0.889), and ROC AUC 0.976 (bootstrap CI 0.975-0.976). Category AUC ranged from 0.921 to 0.994. MRMC reader study used 24 readers and 238 cases from 9 US centers: reader AUC improved 0.836 to 0.894, sensitivity 0.757 to 0.856, and specificity 0.843 to 0.870 with Chest-CAD assistance
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Concurrent CADe reading aid that identifies, categorizes, and highlights suspicious regions of interest on adult chest radiographs
DICOM Presentation State overlay for each image with ROI category text and bounding boxes when suspicious ROIs are detected, or No ROI(s) Detected with no boxes; overlay can be toggled in the PACS viewer
Indicated for adults only and intended as an assistive concurrent read; suspicious categories are broad ROIs rather than a single disease diagnosis, and physician interpretation remains necessary
Standalone testing used 20,000 chest radiographs from 12 US hospitals, outpatient centers, and specialty centers: overall sensitivity 0.908 (95% CI 0.905-0.911), specificity 0.887 (0.885-0.889), and ROC AUC 0.976 (bootstrap CI 0.975-0.976). Category AUC ranged from 0.921 to 0.994. MRMC reader study used 24 readers and 238 cases from 9 US centers: reader AUC improved 0.836 to 0.894, sensitivity 0.757 to 0.856, and specificity 0.843 to 0.870 with Chest-CAD assistance
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Standalone testing used 20,000 chest radiographs from 12 US hospitals, outpatient centers, and specialty centers: overall sensitivity 0.908 (95% CI 0.905-0.911), specificity 0.887 (0.885-0.889), and ROC AUC 0.976 (bootstrap CI 0.975-0.976). Category AUC ranged from 0.921 to 0.994. MRMC reader study used 24 readers and 238 cases from 9 US centers: reader AUC improved 0.836 to 0.894, sensitivity 0.757 to 0.856, and specificity 0.843 to 0.870 with Chest-CAD assistance
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Chest-CAD regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K210666
Samplen=20000
Sites12
IndependenceIndependence not established
K210666
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210666. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Adult digital chest radiograph studies received from a DICOM node
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: FDA packet describes secure cloud-based processing and delivery from a DICOM node to a PACS viewer, where the presentation-state overlay can be toggled; exact current cloud configuration, interfaces, and versions are not otherwise established
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Chest-CAD's platform as secure cloud-based processing in the Proposed Device column of its technological comparison table. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Proposed Device Predicate Platform Secure cloud-based processing" … "Table 1 provides a comparison of the Technological Characteristics of Chest-CAD to the predicate RapidScreen™ RS-2000.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: DICOM Presentation State overlay for each image with ROI category text and bounding boxes when suspicious ROIs are detected, or No ROI(s) Detected with no boxes; overlay can be toggled in the PACS viewer
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM Presentation State overlay for each image with ROI category text and bounding boxes when suspicious ROIs are detected, or No ROI(s) Detected with no boxes; overlay can be toggled in the PACS viewer
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Chest-CAD's platform as secure cloud-based processing in the Proposed Device column of its technological comparison table. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Proposed Device Predicate Platform Secure cloud-based processing" … "Table 1 provides a comparison of the Technological Characteristics of Chest-CAD to the predicate RapidScreen™ RS-2000.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
FDA packet describes secure cloud-based processing and delivery from a DICOM node to a PACS viewer, where the presentation-state overlay can be toggled; exact current cloud configuration, interfaces, and versions are not otherwise established
Imagen's security policy (effective 2024-04-02) states HIPAA, HITRUST CSF and SOC 2 Type II compliance, encryption in transit and at rest, least-privilege access, multi-factor authentication, audit trails and incident response. Vendor statement; no report or certificate was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the policy is on imagen.ai, whose AI software page lists this product by name, and the FDA letter for this entry names Imagen Technologies, Inc. (New York). The policy is company-wide; exact-release scope is not established. A 2023 HITRUST release names the Care Delivery Services platform, not the devices, and is not applied.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K210666 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: Aids dentists reviewing bitewing and periapical radiographs of permanent teeth by detecting/segmenting caries and periapical radiolucencies, identifying restorations and dental anatomy, and measuring mesial/distal bone levels; it does not replace dentist review.
Authorized purpose: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.